您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 7856 处方药 7487 非处方药 253 保健品/医疗用具 116

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国际免费电话:
QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com
投诉与建议:
complaint@shijiebiaopin.com

  药店国别: 法国药房
产地国家: 德国
所属类别: 神经系统药物->抗癫痫药物
处方药:处方药
包装规格: 200毫升/瓶
计价单位:
  点击放大  
生产厂家英文名:
UCB Pharma S.A.
该药品相关信息网址1:
http://www.vimpat.com/
该药品相关信息网址2:
https://www.rxlist.com/vimpat-drug.htm
原产地英文商品名:
VIMPAT 10MG/ML Syrup 200ML
原产地英文药品名:
LACOSAMIDE
中文参考商品译名:
VIMPAT糖漿10毫克/毫升, 200毫升
中文参考药品译名:
拉科酰胺
曾用名:
拉考沙胺
原产地国家批准上市年份:
2008/10/28
英文适应病症1:
seizures
临床试验期:
完成
中文适应病症参考翻译1:
癫痫
药品信息:
------------------------
 详细处方信息以本药内容附件PDF文件(2018101118105217.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

Important Safety Information


VIMPAT (lacosamide) is a medicine that is used with other medicines to treat partial onset seizures in patients 17 years of age and older with epilepsy. VIMPAT is generally well-tolerated, but may not be for everyone. Ask your doctor if VIMPAT is right for you.

The most common side effects with VIMPAT are dizziness, headache, nausea, and double vision.

VIMPAT may also cause problems with coordination and balance. You should not drive, operate machinery or do other dangerous activities until you know how VIMPAT affects you. Do not stop taking VIMPAT without first talking to your doctor. Stopping VIMPAT suddenly can cause serious problems. VIMPAT could make you feel faint. Tell your doctor if you have a heart condition or if you are taking other medicines that affect the heart. In rare cases, VIMPAT may cause reactions that could affect your heart, liver or kidney. Contact your doctor immediately if you are tired, have jaundice (yellowing of skin or eyes), and have dark urine. Antiepileptic drugs, including VIMPAT, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your healthcare provider right away if you have new or worsening symptoms of depression, any unusual changes in mood or behavior, or suicidal thoughts, behavior, or thoughts about self harm that you have never had before or may be worse than before.

------------------------------------------------------------------------

You and your neurologist might find that your current epilepsy medicine does not give you the seizure control you need. Adding Vimpat to your epilepsy treatment can mean:

  • Having fewer seizures
  • More seizure-free days
  • Seizure control, no matter how many epilepsy medicines
  • you have taken before or are taking now
  • Little effect on concentration, attention span, or memory
  • Little effect on weight

------------------------------------------------------------------------


Adding another epilepsy medicine to your current treatment can help you better control your partial-onset seizures. That is why you and your neurologist have added Vimpat—a medicine that treats epilepsy.

In almost 10 years of studies, the proven safety profile of Vimpat has shown:

  • Little effect on weight
  • Little effect on concentration, attention span, or memory
  • It is not likely to cause sleepiness
  • It can be taken with most other epilepsy medicines

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20102221004515.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

Lacosamide拉科酰胺(也称拉考沙胺,Vimpat) 


     美国加州圣地亚哥举行的北美地区癫痫会议上,德国Schwarz Pharma公司宣读了其口服lacosamide(Ⅰ)作为成人未控制的部分性惊厥的辅助治疗的Ⅲ期试验中安全性和疗效的阳性资料。(Ⅰ)200mg/日和(Ⅰ)400mg/日两组都显示比安慰剂组有统计学显著的和临床相关的改善。在过去用过三种不同的抗癫痫药仍不能控制的患者中同时加用(Ⅰ)后一般能很好耐受。
    拉科酰胺(Lacosamide)是德国Schwarz BioSciences公司研发的治疗癫痫和神经性疼痛的药物。2008年9月欧盟批准UCB公司的拉科酰胺片上市,用于辅助治疗16岁及以上有或无继发性癫痫大发作患者的癫痫部分发作。2008年10月表示美国FDA已批准拉科酰胺上市作为一种辅助药物与其它药物联合用于癫痫部分性发作,商品名为Vimpat。Vimpat获准上市的有2种剂型:薄膜片(50  、100 、150和200 mg/片)、注射液(10 mg/mL,20ml/支),当患者不宜口服时可采用推注给药。


---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(2018101118105217.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2018-10-10
附件:
2018101118105217.pdf    





 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com